Evidence map›Paper›PMID 22649143›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012

Sarcopenia during androgen-deprivation therapy for prostate cancer.

Matthew R Smith, Fred Saad, Blair Egerdie, Paul R Sieber, Teuvo L J Tammela, Chunlei Ke, Benjamin Z Leder, Carsten Goessl

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07057375 (A Prospective Randomized Study to Investigate the Effect of Pulsed Electromagnetic Field Therapy on Muscle Mass and Muscle Strength in Prostate Cancer Patients Treated With Androgen Deprivation Therapy), which is not on this map. Cited by 105 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07057375 narecruitingnot on this mapstarted 2025, after this paper: background citation

A Prospective Randomized Study to Investigate the Effect of Pulsed Electromagnetic Field Therapy on Muscle Mass and Muscle Strength in Prostate Cancer Patients Treated With Androgen Deprivation Therapy

TypeinterventionalSponsorChinese University of Hong KongRan2025 to 2027Enrolled110ConditionsProstate CancerArmsPulsed electromagnetic fields Thearpy, Sham Therapy
3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Fasting during cancer treatment: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023
    Pooled it
  4. Pooled it
  5. Does Androgen Deprivation for Prostate Cancer Affect Normal Adaptation to Resistance Exercise?International journal of environmental research and public health · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Matthew R SmithMassachusetts General Hospital Cancer Center, Yawkey 7030, 55 Fruit St, Boston, MA 02114, USA. smith.matthew@mgh.harvard.edu
Fred Saad
Blair Egerdie
Paul R Sieber
Teuvo L J Tammela
Chunlei Ke
Benjamin Z Leder
Carsten Goessl

Funding

Midcareer Investigator AwardK24CA121990 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SMITH, MATTHEW RAYMOND · 2007 to 2016
$1.9M
NCI NIH HHS 5K24CA121990NCI NIH HHS K24 CA121990
6 · The paper itself

Abstract

purposeTo characterize changes in lean body mass (LBM) in men with prostate cancer receiving androgen-deprivation therapy (ADT). PATIENTS AND

methodsWe prospectively evaluated LBM in a prespecified substudy of a randomized controlled trial of denosumab to prevent fractures in men receiving ADT for nonmetastatic prostate cancer. LBM was measured by total-body dual-energy x-ray absorptiometry at study baseline and at 12, 24, and 36 months. The analyses included 252 patients (132, denosumab; 120, placebo) with a baseline and at least one on-study LBM assessment. Patients were stratified by age (< 70 v ≥ 70 years) and by ADT duration (≤ 6 v > 6 months).

resultsMedian ADT duration was 20.4 months at study baseline. Mean LBM decreased significantly from baseline, by 1.0% at month 12 (95% CI, 0.4% to 1.5%; P < .001; n = 248), by 2.1% at month 24 (95% CI, 1.5% to 2.7%; P < .001; n = 205), and by 2.4% at month 36 (95% CI, 1.6% to 3.2%; P < .001; n = 168). Men age ≥ 70 years (n = 127) had significantly greater changes in LBM at all measured time points than younger men. At 36 months, LBM decreased by 2.8% in men age ≥ 70 years and by 0.9% in younger men (P = .035). Men with ≤ 6 months of ADT at study entry (n = 36) had a greater rate of decrease in LBM compared with men who had received more than 6 months of ADT at study entry (3.7% v 2.0%; P = .0645).

conclusionIn men receiving ADT, LBM decreased significantly after 12, 24, and 36 months.

Indexed as

Absorptiometry, PhotonAgedAndrogen AntagonistsAntibodies, Monoclonal, HumanizedBody CompositionBone DensityDenosumabHumansMaleProstatic NeoplasmsSarcopeniaAndrogen AntagonistsAntibodies, Monoclonal, HumanizedDenosumab

Identifiers

PMID22649143
PMCPMC3434987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.